Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

US11248035B1 · kind B1 · utility

Assignee

• Immatics Biotechnologies GmbH · DE

Inventors

• Heiko SCHUSTER · Rötteln, DE
• Janet Peper · Freising, DE
• Kevin Roehle · Rötteln, DE
• Philipp Wagner · Mellrichstadt, DE
• Hans-Georg Rammensee · Lörrach, DE

Key dates

• Filing date: Jun 11, 2021
• Grant date: Feb 15, 2022
• Expiry date: Jun 11, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.